H
Hanall Biopharma Co Ltd
KRX:009420
Hanall Biopharma Co Ltd
KRX:009420
Price:
55 100
KRW
-2.3%
Market Closed
Market Cap:
₩2.9T
Relative Value
The Relative Value of one Hanall Biopharma Co Ltd stock under the Base Case scenario is 4 928.19 KRW. Compared to the current market price of 55 100 KRW, Hanall Biopharma Co Ltd is Overvalued by 91%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
4 928.19
KRW
Overvaluation 91%
H
Multiples Across Competitors
Competitors Multiples
Hanall Biopharma Co Ltd Competitors
Hanall Biopharma Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
H
|
Hanall Biopharma Co Ltd
KRX:009420
|
2.8T KRW | 18.2 | 1 211.1 | 375.6 | 725.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD | 14.7 | 46.5 | 31.3 | 33.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF | 4.8 | 31.1 | 13.1 | 15.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP | 5.5 | 31.6 | 17.4 | 24.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF | 5.5 | 22.2 | 13.7 | 17.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD | 4.7 | 16.7 | 10.4 | 12.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.3 | 13 | 9.5 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD | 2.4 | 19.5 | 7.3 | 9.7 | |
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR | 2.8 | 15.8 | 8 | 11.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
